Biologically Active Ligand-Bearing Polymer-Grafted Liposomes

Introduction of polymer-grafted lipid vesicles allowed to overcome some of the shortcomings of classical liposomes pertaining to their use in drug delivery, e.g. short circulating lifetimes in vivo with concomitant uptake by liver and spleen (Woodle, 1997). Optimal formulations of polymer-grafted liposomes contain 3–7 mole % of methoxypolyethylene glycol (MW 2000)-distearoylphosphatiyl-ethanolamine (mPEG-DSPE) in addition to various amounts of lecithin and cholesterol (Lasic and Martin, 1995).